Literature DB >> 7411526

C-reactive protein in the evaluation of antibiotic therapy for pelvic infection.

N S Angerman, M I Evans, W D Moravec, G F Schumacher, S N Hajj.   

Abstract

C-reactive protein (CRP), an acute-phase reactant not found in normal serum, has previously been shown, by qualitative assay, to differentiate inflammatory from noninflammatory pelvic pathology. In this study, quantitative measures of serum CRP were obtained concomitantly with white blood counts (WBC) and erythrocyte sedimentation rates (ESR) in patients being treated for pelvic infection. CRP levels and their changes, which were not known to physicians treating the patients, accurately indicated those patients who would need supplementary antibiotics to achieve remission. WBC levels were misleading in over half the patients, and the ESR bore no relationship to the clinical situation. The data suggest that CRP may be used to assess the efficacy of antibiotic therapy in pelvic infection. Our successful use of single-agent therapy in most cases also suggests that the use of multiple antibiotics is unnecessary and that CRP levels can indicate when additional antibiotics are appropriate.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7411526

Source DB:  PubMed          Journal:  J Reprod Med        ISSN: 0024-7758            Impact factor:   0.142


  3 in total

1.  Serum CRP in the diagnosis and treatment of pelvic inflammatory disease.

Authors:  M Hemilä; L Henriksson; O Ylikorkala
Journal:  Arch Gynecol Obstet       Date:  1987       Impact factor: 2.344

2.  C-reactive protein in patients with bacteremia.

Authors:  R E McCabe; J S Remington
Journal:  J Clin Microbiol       Date:  1984-09       Impact factor: 5.948

3.  Gas chromatography-mass spectrometric method-based urine metabolomic profile of rats with pelvic inflammatory disease.

Authors:  Wei Zou; Xiaoke Wen; Xiaoqi Sheng; Y I Zheng; Zuoqi Xiao; Jieying Luo; Shuqiong Chen; Yichao Wang; Zeneng Cheng; Daxiong Xiang; Yichu Nie
Journal:  Exp Ther Med       Date:  2016-03-10       Impact factor: 2.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.